Delving into the Latest Updates on Nesiritide Recombinant with Synapse

Overview

Basic Info

Drug Type

Recombinant polypeptide, Cyclic Peptide

Synonyms

BNP, Brain natriuretic peptide, Brain natriuretic peptide 32

+ [11]

Target

NPRA

Action

agonists

Mechanism

NPRA agonists(Natriuretic peptide receptor 1 agonists)

Therapeutic Areas

Cardiovascular DiseasesRespiratory DiseasesUrogenital Diseases+ [1]

Active Indication-

Inactive Indication

Acute congestive heart failureAcute decompensated heart failureAcute Kidney Injury+ [15]

Originator Organization

Johnson & Johnson

Active Organization-

Inactive Organization

Scios, Inc.

Chengdu Shengnuo Biotechnology Co., Ltd.Janssen-Cilag Pty Ltd.

+ [3]

License Organization

Scios, Inc.

Johnson & Johnson

Drug Highest PhaseWithdrawn

First Approval Date

United States (10 Aug 2001),

Acute decompensated heart failure

Regulation-

Login to view timeline

Structure/Sequence

Sequence Code 37334

Source: *****

Hypoxia is a distinctive characteristic of solid tumors, limiting the efficiency of photodynamic therapy (PDT). In this study, transcriptomics was applied to analyze the changes in mRNA levels in mouse tumors treated with multiple photodynamic therapy sessions, revealing that 12 genes in the PI3K/mTOR pathway were significantly upregulated. In order to improve delivery efficiency and enhance the efficacy of PDT photosensitizers, a nitroreductase-responsive BODIPY prodrug (BNP) was designed and employed to encapsulate a PI3K/ mTOR dual inhibitor (BEZ235) to self-assemble into nanoparticles (BNP@BEZ NPs). The fluorescence level of BNP@BEZ NPs in hypoxic cells was 12.20-fold that in normoxic cells because of the responsiveness of nitrobenzyl groups to hypoxia. Such minimized off-target effects also resulted in preferential intratumoral activation of prodrugs. Meanwhile, BEZ co-loading alleviated tumor hypoxia and increased intracellular ROS levels to 155.26% compared to blank prodrug nanoparticles. BNP@BEZ NPs-mediated PI3K/mTOR inhibition and apoptosis of tumor cells exhibited sufficient antitumor efficacy with a tumor inhibition rate of 93.31%. In conclusion, this study confirms that the PI3K/mTOR pathway promotes tumor PDT resistance by enhancing mitochondrial respiration. The hypoxic -responsive photodynamic properties of BNP, combined with BEZ's oxygen consumption-inhibiting capacity, can enhance tumor suppression rates. This strategy of nanomedicine development by capitalizing on the synergistic effect between active ingredients will avoid the low efficacy and adverse effects of monotherapies.

01 Aug 2026·Biomaterials advances

Synergism of microgrooves and gallium phytate coating on PEKK based percutaneous implant with photothermal effect facilitates biological sealing of skin tissue for combating infection

Article

Author: Sun, Ping ; Xie, Shangyu ; Niu, Yunfei ; Zhou, Yang ; Li, Wenyang ; Ma, Susu ; Wei, Jie

The success of percutaneous implants not only involves integration with bone tissue but also requires integration with soft tissue to form bio-sealing, which effectively prevents epithelial downgrowth and resists infection. Herein, black niobium oxide/polyetherketoneketone (PEKK) composite (BNP) with photothermal performance was fabricated, and microgrooves with widths of 30 μm, 50 μm, and 80 μm were created on BNP by femtosecond laser. BNP with a width of 50 μm (BNPg50) obviously facilitated the responses (e.g., migration and differentiation) of fibroblasts (L929 cells) and epidermal keratinocytes (JB-6 cells), and their co-culturing as well as stimulated macrophage M2 polarization. Moreover, gallium phytate (GP) was coated on BNPg50 (BNPgG), which exhibits excellent antibacterial properties for killing bacteria in vitro and resisting infection in vivo due to the synergism of Ga ions and photothermal effect. Further, BNPgG obviously facilitated the proliferation of bone marrow mesenchymal stem cells (BMSCs) while inhibiting bacterial growth under near infrared in co-culturing of cells and bacteria. The in vivo experiments demonstrated that synergies of microgrooves, GP coating, and photothermal effect remarkably encouraged bio-sealing of skin tissue for combating infection. This fundamental research advanced the understanding of soft tissue responses and biological sealing around implants, thereby highlighting their great potential for accelerating the application of percutaneous implants.

01 Jun 2026·PEDIATRIC CARDIOLOGY

NT-pro Brain Natriuretic Peptide in Infants with Single Ventricle Heart Disease in the CHAMP® Multi-site Registry

Article

Author: Noel-Macdonnell, Janelle R ; Romans, Ryan A ; Ricketts, Amy ; Jayaram, Natalie ; Elliott, Melissa ; Erickson, Lori A ; Desai, Atharva ; Hancock, Hayley S ; Moehlmann, Matthew

The role of NT-pro Brain Natriuretic Peptide (NT-proBNP) and BNP in single ventricle (SV) patients during the interstage period is not well understood. We sought to describe NT-proBNP and BNP in a large group of SV infants and to determine if there is an association between pre-discharge NT-proBNP and interstage outcomes (unplanned hospitalizations [UPH]/interventions). We identified SV infants at 11 Cardiac High Acuity Monitoring Program (CHAMP) centers from 2014 to 2021 using the CHAMP multisite registry. Patients with NT-proBNP/BNP drawn prior to neonatal discharge were included, with the last value identified. Demographics, clinical characteristics, and events were collected. zlog transformation was used to convert NT-proBNP values to a normal distribution. Two-sided t-tests (α = 0.05) were used to evaluate average differences in zlog transformed NT-proBNP between patients with an UPH/intervention versus those with neither. 268 patients (male = 178, 66.4%) were included. The most common diagnosis was hypoplastic left heart syndrome, (N = 105, 39.2%). Median NT-proBNP (N = 136) and BNP (N = 132) were 5295 (IQR 2905-8590) and 299 (IQR 158-543), respectively, with median zlog-NT-proBNP 2.87 (IQR 2.24, 3.55). UPH/interventions occurred in 142 patients (53%). There was no significant difference in zlog-NT-proBNP in patients with UPH/interventions versus neither (p-value = 0.872). We described BNP, NT-proBNP, and zlog-NT-proBNP in SV infants at interstage discharge. Further investigation is needed to understand whether NT-proBNP/BNP and zlog-NT-proBNP can prognosticate outcomes after initial SV/interstage discharge.

2

News (Medical) associated with Nesiritide Recombinant

19 Oct 2023

·www.sciencedaily.com

BNP peptide a culprit in eczema

Researchers have pinpointed a particular peptide's role in activating atopic dermatitis, or eczema. The work could lead to more effective treatments for the condition. Researchers from North Carolina State University have pinpointed a particular peptide's role in activating atopic dermatitis, or eczema. The work could lead to more effective treatments for the condition. Atopic dermatitis (AD) is a skin condition characterized by itching, irritated and thickened skin at the site of the irritation. The brain natriuretic peptide (BNP) is a peptide, or short chain of amino acids, that is elevated in patients with AD. "BNP is expressed in sensory neurons, the neurons responsible for conveying sensation to the brain via the spinal cord," says Santosh Mishra, associate professor of molecular biomedical sciences at NC State and corresponding author of the work. "We know from previous work that BNP helps translate the sensation of itch from the skin to the brain. In this work we wanted to see if BNP was involved in activating AD." In a chemically induced mouse model of AD, the researchers saw that mice without BNP did not exhibit the thickened or irritated skin commonly associated with AD, and their itching was reduced compared with control mice who did have BNP. "The results show that BNP likely plays a role in itch activation," Mishra says. "We next looked at BNP's relationship to periostin, to see if we could determine how that activation takes place." Periostin is a protein that can interact with sensory neurons in skin to activate itch response. It is produced in skin cells called keratinocytes and fibroblasts. Keratinocytes in turn, have receptors for BNP, which are called NPR1 receptors. When the BNP receptors are activated, periostin is produced and itch can be turned on. "But the interesting thing here is that the sensory neurons are the activator," Mishra says. The neuron releases BNP, which activates keratinocytes with the NPR1 receptor, which then release the periostin. "This work shows that peripheral neurons, not just central neurons, are playing a role in AD -- it begins in the sensory neurons, and cascades from there," Mishra adds. "It also points to some potential therapeutic strategies, such as blocking BNP's ability to bind to NPR1 receptors in the skin." The research appears as a letter to the editor in the Oct. 11 issue of the Journal of Investigative Dermatology. The work was supported by the National Institutes of Health under grant number 1R56AR077692-01. NC State undergraduate student Junho Yu, former NC State undergraduate student Nidha Williams, and NC State postdoctoral research scholar Joshua Wheeler, also contributed to the work.

26 Apr 2023

·www.prnewswire.com

The Role of Natriuretic Peptides in the Diagnosis and Management of Heart Failure Discussed in New Joint Scientific Statement by the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, and Japanese Heart Failure Society

ROCKVILLE, Md., April 26, 2023 /PRNewswire/ -- The Heart Failure Society of America (HFSA), the Heart Failure Association of the European Society of Cardiology (HFA-ESC) and the Japanese Heart Failure Society (JHFS) announced today a joint scientific statement on Natriuretic Peptides: Role in the Diagnosis and Management of Heart Failure. Natriuretic peptides, brain (B-type) natriuretic peptide (BNP) and N-terminal prohormone of brain natriuretic peptide (NT-proBNP), are internationally used as a biomarker for diagnosis and management in adults with heart failure (HF). In addition, natriuretic peptide biomarker data can be important in risk stratification of heart failure prognosis. In addition to biomarker data, implementation of an oral angiotensin receptor neprilysin inhibitor (ARNI) has increased healthcare professionals' awareness of natriuretic peptides as an important therapeutic agent. Natriuretic Peptides: Role in the Diagnosis and Management of Heart Failure scientific statement aims to provide a framework and expert recommendations to healthcare professionals on the diagnosis and management of HF and focuses on the following areas: History and basic research: discovery, production, and cardiovascular protection Diagnostic and prognostic biomarkers: acute HF, chronic HF, inclusion/endpoint in clinical trials, and natriuretic peptides-guided therapy Therapeutic use: nesiritide (BNP), carperitide (ANP), and sacubitril (neprilysin inhibitor [combined with an angiotensin receptor blocker]), and Gaps in knowledge and future directions Standardized screening for HF remains challenging because of the heterogeneity of risk factors across different patient populations. Natriuretic peptides are recommended for initial diagnosis of HF as noted in the 2022 ACC/AHA/HFSA Guideline for the Management of HF, 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic HF, and JCS2017/JHF2017 Guideline on diagnosis and treatment of acute and chronic HF. "There are several differences in the statements among HF Societies regarding the use of natriuretic peptides as biomarkers for risk stratification and prevention. The scientific statement provides up-to-date perspectives and guidance that healthcare professionals can use to navigate and provide the best care for their patients with HF," Nancy Albert, PhD, CCNS, CHFN; co-chair and co-author representing HFSA in the Trilateral International Consensus Conference (TICC) said. The joint scientific statement on natriuretic peptides was developed by the TICC, a collaboration of HFSA, JHFS and HFSA-ESC. The TICC 2021 was hosted by the JHFS and was chaired by Hiroyuki Tsutsui, President of the JHFS, with Nancy M. Albert (HFSA) and Andrew Coats (HFA-ESC) serving as co-chairs. The Natriuretic Peptides: Role in the Diagnosis and Management of Heart Failure scientific statement will jointly publish on Monday 17 April at 9:00 AM EDT in the Journal of Cardiac Failure, the official journal of the HFSA and the JHFS, and the European Journal of Heart Failure, the official journal of the HFA-ESC. DOI: 10.1016/j.cardfail.2023.02.009 To receive a copy of the manuscript in advance of the embargo, contact [email protected]. About the Heart Failure Society of America The Heart Failure Society of America, Inc. (HFSA) represents the first organized effort by heart failure experts from the Americas to provide a forum for all those interested in heart function, heart failure, and congestive heart failure (CHF) research and patient care. The mission of HFSA is to provide a platform to improve and expand heart failure care through collaboration, education, innovation, research, and advocacy. HFSA members include physicians, scientists, nurses, nurse practitioners, pharmacists, trainees, other healthcare workers and patients. For more information, visit hfsa.org. About the Heart Failure Association of the European Society of Cardiology As the world's largest heart failure association, the Heart Failure Association of the ESC prioritizes patient management and awareness of heart failure as a global health problem. HFA-ESC's mission is to improve quality of life and longevity through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research. Learn more online. About the Japanese Heart Failure Society In response to the increased interest in heart failure, based on the basic studies on its mechanisms and clinical trials, the Japanese Heart Failure Society (JHFS) was established in 1996. The first General and Scientific Meeting of the JHFS was held in October 1997 at the Kyoto International Conference Center. The number of members increased from 900 to approximately 4000 in 2020. The vision of JHFS is to enrich the happy life of the patients and their families through investigating the basic pathophysiology of heart failure, and developing the effective and efficient diagnosis, prevention and treatment strategies. About the Journal of Cardiac Failure The Journal of Cardiac Failure (JCF) publishes the highest quality science in the field of heart failure with a focus on diversity, equity, and inclusion, mentorship, multidisciplinary partnerships, and patient-centeredness. Published papers span original investigator-initiated work to state-of-the-art reviews, guidelines and scientific statements, expert perspectives, early career and trainee spotlight pieces, patient and patient-partner narratives. JCF also emphasizes the power of language and prioritizes innovative approaches to dissemination of published work to reach and impact the broader heart failure community. For more information, visit onlinejcf.com. About the European Journal of Heart Failure The European Journal of Heart Failure (EJHF) is dedicated to the advancement of knowledge in the field of heart failure management. The journal publishes reviews and editorials to improve the understanding, prevention, investigation and treatment of heart failure. Molecular and cellular biology, pathology, physiology, electrophysiology, pharmacology, as well as clinical, social and population sciences all form part of the discipline. Visit EJHF online. Media Contact: Laura Poko: Director of Marketing and Communications, Heart Failure Society of America, 301-798-4493, ext. 226 [email protected] Olivia Seward: Associate Director Communication, European Society of Cardiology, +33 (0)4 89 87 20 10, [email protected] SOURCE Heart Failure Society of America

100 Deals associated with Nesiritide Recombinant

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	Nesiritide Recombinant	C01DX19	DB04899

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Acute decompensated heart failure	United States	Scios LLC	10 Aug 2001

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Coronary Artery Disease	Phase 3	-	Scios, Inc.	17 Sep 2007
Pulmonary Disease, Chronic Obstructive	Phase 3	Australia	Janssen-Cilag Pty Ltd.	01 Sep 2007
Cardiomyopathies	Phase 3	-	Scios, Inc.	01 Jan 2001
Dyspnea, Paroxysmal	Phase 3	-	Scios, Inc.	01 Jan 2001
Acute congestive heart failure	Phase 3	-	Scios, Inc.	01 Oct 1999
Decompensated chronic heart failure	Phase 3	-	Scios, Inc.	01 Oct 1999
Heart failure NYHA class IV	Phase 3	-	Scios, Inc.	01 Aug 1998
Chronic congestive heart failure	Phase 3	-	Scios, Inc.	01 Oct 1996
Heart Failure	Phase 3	-	Scios, Inc.	01 Oct 1996
Ventricular Dysfunction, Left	Phase 2	United States	Scios, Inc.	01 Mar 2008

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT00281671 (CTgov)	Phase 1/2	Heart Defects, Congenital	9	Placebo (Placebo)	hjvhimwfaz(cvdpfdwhjz) = yqqfppazvw rrxkvfgkqh (kvalcxzcei, iffyfyhabw - yqqddtvxzr) View more	-	27 Aug 2020
				nesiritide (Nesiritide)	hjvhimwfaz(cvdpfdwhjz) = bunfnmayip rrxkvfgkqh (kvalcxzcei, aronayirsb - fimphaknho) View more
NCT00543309 (CTgov)	Phase 2	Heart Defects, Congenital	106	nesiritide (I- Nesiritide)	xjttjzgmwt(rttsghnyli) = elazncyjqt swiuumtvce (emrynbbnxw, osbkilordo - hcllsavlrv) View more	-	25 Jun 2018
				milrinone (II- Milrinone)	xjttjzgmwt(rttsghnyli) = kpaybgvbgf swiuumtvce (emrynbbnxw, wncatshktp - yxvkqspimo) View more
NCT00475852 (ASCEND-HF, Pubmed \| Circ Heart Fail)	Phase 3	Acute decompensated heart failure	7,141	Nesiritide (High enrolling sites)	uzhokncuzk(gjhdfxyeea): hazard ratio = 0.99 (95% CI, 0.98 - 1.01) View more	-	01 Sep 2016
				Nesiritide (Low enrolling sites)
NCT00475852 (ASCEND-HF, Pubmed \| BMJ Open)	Phase 3	Heart Failure	1,068	Nesiritide (Self-presentation)	ocjvxezyti(nratjraprb) = lfhelixjkc ropkguwmdx (zotgczcyic ) View more	-	17 Mar 2016
				Nesiritide (Ambulance)	ocjvxezyti(nratjraprb) = phwuvqqcyc ropkguwmdx (zotgczcyic ) View more
NCT00475852 (ASCEND-HF, Pubmed \| J Am Heart Assoc)	Phase 3	Heart Failure \| Atrial Fibrillation	7,007	nesiritide (Patients with AF)	ganakxlttr(ojfrnryksw) = nlowiruhbr oujqkkwcmt (zdbzenpilz )	-	24 Aug 2015
				nesiritide (Patients without AF)	ganakxlttr(ojfrnryksw) = ezdkvlcwtw oujqkkwcmt (zdbzenpilz )
NCT01544998 (CTgov)	Phase 1/2	Depressive Disorder \| Heart Failure \| Renal Insufficiency	43	Tadalafil+Nesiritide (Tadalafil Plus Nesiritide)	mthljnumtp(lnzuoinljk) = xrniwkrsve urfwtdhjpt (evwakxscag, 161.8) View more	-	04 Mar 2015
				Placebo+Tadalafil (Tadalafil Plus Placebo)	mthljnumtp(lnzuoinljk) = qxghhapgtg urfwtdhjpt (evwakxscag, 86.5) View more
NCT00475852 (ASCEND-HF, Pubmed \| Circulation)	Phase 3	Acute decompensated heart failure	7,141	Nesiritide	jnmlhwqyxh(emnuptoazd) = njukmgpnve pcuhyhvwnf (eifdidzgtz ) View more	-	16 Sep 2014
				Placebo	jnmlhwqyxh(emnuptoazd) = pmxsuqkdut pcuhyhvwnf (eifdidzgtz ) View more
NCT00573144 (Believe II, CTgov)	Phase 2	Anterior Wall Myocardial Infarction \| Acute myocardial infarction	59	Placebo (Placebo)	dlyezzowcd(thrpamlxkq) = lcftjljftf vmzuoakegs (lfcfospgyb, 58) View more	-	09 Sep 2014
				Nesiritide (Nesiritide)	dlyezzowcd(thrpamlxkq) = xlmwctpsem vmzuoakegs (lfcfospgyb, 31) View more
NCT01132846 (ROSE/RED ROSE \| ROSE AHF \| ROSE, CTgov)	Phase 2	Dyspnea \| Heart Failure	360	Dopamine (Low Dose Dopamine)	ekyvidagoc(bfgbdokisx) = almwwvuxri uzzmittmdl (jshhfvuzlk, .32) View more	-	21 Aug 2014
				Placebo (Placebo)	ekyvidagoc(bfgbdokisx) = tpmrjkrokg uzzmittmdl (jshhfvuzlk, .27) View more
NCT01836809 (CTgov)	Phase 4	Cardio-Renal Syndrome	2	nesiritide (Total Artificial Heart)	rafhrsuvhd(irvgxiqoif) = sfsuewjjka mhhrgktymv (flnxdmvwfv, aubhrchfid - ptgyidtgtx) View more	-	18 Aug 2014
				placebo (Total Artificial Heart: Placebo)	rafhrsuvhd(irvgxiqoif) = owhiyefmpj mhhrgktymv (flnxdmvwfv, evcbooyugn - tidyqgfbli) View more

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.

login

or

view full example data

Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.

login

or

view full example data

Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.

login

or

view full example data

Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.

login

or

view full example data

Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.

login

or

view full example data

Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

login

or

view full example data